Boehringer Ingelheim | pharmaphorum

Wednesday 22 January 2025

Channels

Content type

Categories

Categories

Sort by

Order

Boehringer Ingelheim

News

Boehringer drug for brain fog in schizophrenia fails trial

Boehringer drug for brain fog in schizophrenia fails trial

Boehringer Ingelheim's bid to develop the first drug therapy for impaired cognitive function in schizophrenia looks like it has reached an end.

Sales & Marketing

Veeva Summit - Chris Moore, president of Veeva Europe

A next-generation mindset: Veeva Commercial Summit 2024

Imagine a time when all your teams collaborate seamlessly. That’s what this year’s Veeva Commercial Summit posited as it commenced.

Patients

hands holding paper head representing protecting the mind

Keeping stigma out of it: Personalising the mental health co...

Thursday 10th October was World Mental Health Day, focused this year on ‘mental health at work’.

News

Handshake across business plans

Ono, Boehringer add to cancer pipelines with licensing deals

Ono Pharma and Boehringer Ingelheim both added to their cancer pipelines, licensing drugs from LigaChem Bio and Circle Pharma, respectively.

R&D

Richard Young, Nicole Raleigh, Daniel Schwenk and Andrea Kloeble

Boehringer Ingelheim and Veeva: A data partnership for One M...

Boehringer’s Medicine Excellence initiative harnesses technology with the aim to build a ‘One Medicine Platform’, unifying development processes and data in a centralised platform.

News

Trial sets up filings for Boehringer IPF drug nerandomilast

Trial sets up filings for Boehringer IPF drug nerandomilast

With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy O